
News|Articles|March 1, 2011
FDA Pipeline Preview, March 2011 (Contrave, rabeprazole sodium extended-release capsules, Avodart, Mu Delta, Carfilzomib, Vascugel, INX-0818, vosaroxin, Acurox, fidaxomicin, melanoma cancer vaccine, NSI-566RSC, Regorafenib)
Recent FDA action (through, February 2011) related to Contrave, rabeprazole sodium extended-release capsules, Avodart, Mu Delta, Carfilzomib, Vascugel, INX-0818, vosaroxin, Acurox, fidaxomicin, melanoma cancer vaccine, NSI-566RSC, Regorafenib.
Advertisement
Complete response
Fast-track designation
Priority review
Orphan drug designations
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Medicare Part D redesign reshapes market
2
A conversation with Tiffany Phung, Pharm.D., CSP, about how patient outcomes drive specialty pharmacy strategy
3
The sleep doctor who lives with a disorder he treats
4
Managing Chronic Disease Shouldn't Feel Like a Full-Time Job
5













